A 58-year-old man with rheumatoid arthritis develops a maculopapular rash 2 weeks after starting methotrexate. The rash is not dose-dependent and occurs despite using the drug at standard therapeutic doses. Which classification of adverse drug reaction does this represent, and what is the best discriminating feature from Type A reactions?

Explanation

## Classification of Methotrexate-Induced Rash: Type B Reaction **Key Point:** The rash occurring at standard therapeutic doses, independent of dose escalation, and unpredictable from methotrexate's known pharmacology (immunosuppression, antifolate activity) is a **Type B (Bizarre) reaction**. ### Clinical Scenario Analysis **Presentation features:** - Onset: 2 weeks after initiation (relatively early, but not immediate) - Dose: Standard therapeutic dose (NOT excessive) - Dose-dependence: **NOT dose-dependent** — occurs at standard doses - Predictability: Unpredictable; not all patients on methotrexate develop rash - Mechanism: Not an exaggeration of known antifolate or immunosuppressive effect These features are pathognomonic for **Type B reaction**. ### Type A vs Type B: Discriminating Features | Feature | Type A | Type B | This Case | |---------|--------|--------|----------| | Dose-dependence | **Yes** | **No** | No ✓ | | Predictability | Predictable | Unpredictable | Unpredictable ✓ | | Dose at occurrence | High/excessive | Standard/therapeutic | Standard ✓ | | Mechanism | Known pharmacology | Idiosyncratic/allergic | Unknown ✓ | | Incidence | Common | Rare | Rare ✓ | | Management | Dose reduction | Permanent withdrawal | Withdrawal ✓ | **High-Yield:** The **absence of dose-dependence** is the single most reliable discriminator. Type A reactions worsen with increasing dose; Type B reactions occur unpredictably at any dose. **Clinical Pearl:** Methotrexate-induced rash is a Type B reaction. Other Type B reactions to methotrexate include: - Hepatotoxicity (cirrhosis, not dose-dependent) - Pneumonitis (unpredictable, not related to dose) - Bone marrow suppression (idiosyncratic, can occur at standard doses) In contrast, methotrexate-induced mucositis or myelosuppression at **very high doses** (e.g., high-dose chemotherapy) would be Type A (dose-dependent). **Mnemonic:** **Type B = Bizarre, unpredictable, Occurs at standard doses, requires permanent avoidance**. ### Why This Is NOT Type A, C, or D - **Not Type A:** Type A reactions are dose-dependent and exaggerate known pharmacology. This rash occurs at standard doses and is not an exaggeration of methotrexate's known effects. - **Not Type C:** Type C reactions represent cumulative toxicity (e.g., liver cirrhosis from chronic methotrexate). A rash at 2 weeks is too early for cumulative toxicity. - **Not Type D:** Type D reactions are teratogenic or mutagenic. This patient is 58 years old (post-reproductive age), and the question does not mention pregnancy or mutagenic concerns.